Pediatric Crohn's Disease Therapy Granted Orphan Drug Designation

The novel treatment is being developed in collaboration with Boehringer Ingelheim
The novel treatment is being developed in collaboration with Boehringer Ingelheim

AbbVie announced that the Food and Drug Administration (FDA) has granted Orphan Drug Designation to risankizumab (ABBV-066) for the investigational treatment of Crohn's disease in pediatric patients

Pediatric patients afflicted with Crohn's disease may experience a delay in growth and sexual maturation and have symptoms similar to those seen in adults, including diarrhea, abdominal pain, rectal bleeding, and weight loss. 

Related Articles

Risankizumab, an IL-23 inhibitor, is being studied for immunological disorders such as Crohn's disease, psoriasis, psoriatic arthritis, and asthma. It is being developed in collaboration with Boehringer Ingelheim.

For more information call (800) 633-9110 or visit AbbVie.com

Loading links....